New anticancer medicines approved by the EMA in 2025
De Remediis · 01.07.2026 · 2 (2)
DOI: 10.71116/qkf6by41 ↗Kurz gefasst
Fachartikel in der Zeitschrift De Remediis, online erschienen am 01.07.2026. Verfasst von Miklós Bege und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the serious progress in the antitumor therapy, cancer did not cease to be one of the leading causes of death in the developed world. Hence still there is high interest for new anticancer agents. In 2025, the EMA approved 104 new medicines, 37 of them containing new active substances. 18 new anticancer medicines were approved (14 new active substances). In this review, we aim to shortly summarize the mechanism of action and use of the new drugs approved by the EMA in the year 2025.
Zitieren
APA
Bege, M., & Borbás, A. (2026). New anticancer medicines approved by the EMA in 2025. De Remediis, 2(2). https://doi.org/10.71116/qkf6by41
Vancouver
Bege M, Borbás A. New anticancer medicines approved by the EMA in 2025. De Remediis. 2026;2(2). doi:10.71116/qkf6by41
BibTeX
@article{Bege2026,
author = {Bege, Miklós and Borbás, Anikó},
title = {New anticancer medicines approved by the EMA in 2025},
journal = {De Remediis},
year = {2026},
volume = {2},
number = {2},
doi = {10.71116/qkf6by41}
}
EUVIMED